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400 Editorials 
start of a disease spectrum with cervical 
spondylosis as the end product, it is important 
to point out that, in Jeffreys' series, 30% of 
patients had sufficient extruded disc material 
to play an important role in compression of the 
cord in addition to that of osteophytic protru- 
sion. 
The role of trauma in the development of 
CSM is interesting; Jeffreys7 found that 10% 
gave a history of a neck injury in the past, 8% 
experienced a neck injury which precipitated a 
neurological decline and 16% gave a history of 
both, i.e. approximately 44% experienced a 
neck injury at some time. Nurick found that 
14% experienced an injury in the month prior 
to admission and which had frequently precipi- 
tated the final decline. It would seem that the 
past neck injury may have contributed to the 
degenerative disease and the precipitating in- 
jury in some way further compromised a spinal 
cord already in jeopardy. 
The role of subluxation in the evolution of 
CSM remains problematical. Jeffreys7 found 
subluxation to be present in 3% whereas 
Nurick4 found that not only did this radiologi- 
cal sign occur in 28.7% but that it tended to be 
associated with increasing disability. One pos- 
sible explanation of this discrepancy may lie in 
the fact that in the former series the patients 
were more disabled and possibly had more 
advanced spondylosis such that their cervical 
spines were more rigid and less able to sublux 
than those in Nurick's series. 
Finally there is the evidence that many 
patients improve greatly and rapidly once the 
compressive agent has been removed, particu- 
larly after anterior cervical decompression and 
f ~ s i o n ~ . ~ .  Whereas one accepts that decom- 
pression successfully carried out could im- 
prove cord blood flow and relieve cord stretch- 
ing the theory most likely to explain a myelo- 
pathy is compression of the spinal cord; 
provided that one also allows that in any 
compression there must be an element of local 
ischaemia in the cord at the site of compres- 
sion, caused by the compressing agent 'squash- 
ing' the vascular bed at that point. 
RICHARD JEFFREYS 
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Dexamethasone and the Serious Head 
Injury 
The serious head injury remains a grave 
medical problem with a mortality of about 40% 
and a good outcome in only 20% in most large 
series round the worldlg. Physical disruption of 
neural tissue, ischaemia and oedema are the 
pathologic substrates in the diffuse brain 
injury2' and therapy aimed at attenuating the 
effects of these on intracranial pressure has 
been the major preoccupation of those caring 
for head injured patients. Thus, after the 
demonstration of a dramatic decrease in cere- 
bral oedema associated with brain tumours by 
dexamethasone", it was not surprising that the 
use of this agent in head injuries rapidly gained 
widespread currency. It is now recommended 
by most standard textbooks and almost univer- 
sally used by physicians other than neurosur- 
geons. Amongst the latter, as so often happens 
in medicine, enthusiasm has been tempered by 
experience. 
Experimental verification of the beneficial 
effects of steroids on post-traumatic cerebral 
oedema was sought soon after their clinical 
introduction. Various animal models and pro- 
tocols were used but conclusions were varied. 
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Blinderman et aL3 demonstrated a reduction in 
oedema induced by intracarotid injection of 
vegetable oil when Solumedrol was infused 
during the procedure. Lippert et al. produced 
oedema in the brain of the dog by implanting 
psyllium seed and began cortisone on the day 
of. operation. Their conclusions were equivo- 
cal. Long et aZ.I8 on the other hand found 
reduction in psyllium induced oedema in the 
rabbit pre-treated with dexamethasone. 
Clasen et aLs produced oedema in monkeys 
by freezing through the intact skull but found 
no benefit of treatment with prednisolone, 
while Benson et aLz were similarly disap- 
pointed when steroids did not significantly 
lessen laser produced oedema in rats. The cold 
injury model was modified to produce local 
cooling of the exposed dura or brain in cats and 
a definite decrease in cerebral oedema was 
observed by Pappius & McCannz3 and 
Maxwell et U Z . ~ O  but not by Dick et d9 or 
Nelsonzz. Kobrine & Kempe16 used a model of 
acceleration-deceleration injury in monkeys 
and found traumatic brain swelling to be 
significantly less in the treated as compared to 
control groups with extension of survival as 
well. On the other hand the acute head injury 
produced in cats with a humane stunner by 
Tarnheim & McLaurinz7 was not affected by 
dexamethasone therapy. All these models have 
concentrated on cerebral oedema and the 
relevance of this to the clinical situation is 
unclear, particularly as the results of clinical 
trials have not been consistent. 
The earliest trials were uncontrolled, such as 
that by Sparacio et ~ 1 . ~ ~  who showed a superior 
outcome in patients with diffuse brain injury 
treated with high dose methylprednisolone 
when compared to the author’s previous exper- 
ience but no benefit to those with focal lesions. 
Looking at patients with traumatic decerebra- 
tion Gutterman et al.I4 concluded that steroids 
did not improve the percentage or quality of 
survival from traumatic decerebration and 
indeed may have had a deleterious effect. 
HoytI5 reported on an unblinded study of 16 
patients treated with placebo and dexametha- 
sone with little difference in mortality. A larger 
number of patients were entered in a similar 
trial by Alexander’ with an 8-year study of 110 
cases of closed head injury equally divided 
between placebo and dexamethasone groups. 
He found “that the use of steroids in the 
acutely injured patient, though probably not 
harmful, is of no real help’’. 
Faupel et aZ.1° reported the first double blind 
study comparing placebo , low dose dexametha- 
sone and high dose dexamethasone in patients 
with severe closed head injury. There was a 
significant reduction in mortality in the treated 
patients (57% in placebo group versus 24% in 
the combined steroid groups). However, it 
must be noted that in the treated group 25.4% 
of the survivors were vegetative compared to 
3.6% of the placebo group and 11.9% were 
severely disabled compared to 7.1% in the 
control group. Thus, benefit of steroid in this 
trial is less clear when death or poor outcome is 
compared to a good or moderate outcome. A 
trial of similar design was reported by Gobiet 
et allz and a significant reduction in mortality 
was claimed. This trial has been criticised on 
statistical grounds and because of incomplete 
data7. Indeed, uncritical acceptance of data 
such as presented in these two trials had given 
dexamethasone an authenticity in head injury 
management it ill-deserved. Gudeman et all3 
in 1979 noted that over the past 10 years 
steroids had come to be used routinely in head 
injury “despite a disconcerting lack of its 
beneficial influence on outcome or on intra- 
cranial pressure in such patients”. Their study 
of 20 cases not only failed to show benefit, 
there was in addition a high incidence of gastric 
haemorrhage and hyperglycaemia. 
Over the past 8 years four prospective 
double-blind controlled trials of high dose 
dexamethasone therapy in head injuries have 
been publicised. Cooper et aL7 studied 76 
patients and found no difference in outcome 
between the treated and placebo group, while 
infectious complications were more frequent in 
the steroid group. The real importance of their 
study was the availability of post-mortem data 
for 32 of the 39 patients who died and this data 
allowed the authors to conclude that 90% of 
the deaths could not be influenced by steroid 
therapy being due either to severe brain 
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injuries with parenchymal haemorrhage and 
tissue disruption, recurrent haematomas or 
medical complications. Saul et aLZ5 studied 100 
comatose patients and there was no significant 
difference in outcome between the two groups 
though in those treated patients responding 
early, a higher incidence of good recovery was 
observed. Braakman et aL4 entered 161 pa- 
tients into their trial and found no difference in 
survival or outcome in the whole group or in 
any sub-group with varying severity of brain 
damage. An increase in pulmonary infection in 
the steroid group was observed. Dearden et aL8 
reported on 130 severely head injured patients 
and found no advantage of high dose dexame- 
thasone on intracranial pressure (ICP) trends 
or clinical outcome. Indeed, treated patients 
with raised ICP fared worse. They also con- 
firmed the hyperglycaemia shown to be more 
frequent in steroid treated patients in previous 
trials. 
During the last few years attention has 
focussed on the metabolic consequences of 
severe head injuries and a profound traumatic 
response identified by increased energy expen- 
diture, a negative nitrogen balance, hypoal- 
buminaemia and weight loss has been foundz8. 
The metabolic response has been estimated to 
be similar to that in patients with burns of 
20-40% of body surface6. This catabolic state 
is accentuated by steroid administration and in 
a study of 20 head injured patients24 random- 
ised to methylprednisolone or no steroid, the 
patients receiving steroid had a 30% higher 
excretion of nitrogen in the first 6 days after 
injury. Immunosuppression, evidenced by a 
lower total lymphocyte count and a higher 
incidence of infections was present in the 
treated group; hyperglycaemia requiring insu- 
lin was more common in those patientsz4. 
Hyperglycaemia has been shown to worsen the 
prospects of a recovery of ischaemic neurones 
in stroke by increasing local lactic acid concen- 
tration and it has been suggested that the same 
may happen in head injuries. Raised intracran- 
ial pressure causes ischaemia particularly in 
the traumatised areas of brain and steroids 
may, by inducing hyperglycaemia and its 
attendant neuronal lactacidosis, be detrimental 
to recovery. If this hypothesis is confirmed, 
steroids may be positively contraindicated in 
head injuries. 
Thus a review of the literature clearly shows 
an emerging consensus that dexamethasone 
confers no benefit to the seriously head injured 
patient and may in fact be harmful. The four 
double blind trials quoted above all contained 
sufficiently large sample sizes and were metho- 
dologically sound enough to make their com- 
bined conclusion unassailable. It is unlikely 
that any further trial will show a contrary 
result. 
RASHID JOOMA 
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